KR890002399A - Hybrid interferon and its preparation method using recombinant DNA technology - Google Patents

Abstract

No content

Description

Hybrid interferon and its preparation method using recombinant DNA technology

Since this is an open matter, no full text was included.

₁ shows plasmid _P RHW _12, which contains the gene sequence IFN-ω _{1 ,}

2 shows plasmids _p SYS ₁₀ , from which the recognition site of restriction enzyme pvuII was removed from plasmid _P ER ₁₀₃ .

3 shows plasmid _P SYS ₁₂₁ containing the gene sequence of hybrid IFN-α _{2 /} ω _{1 .}

Claims (18)

A hybrid interferon of formula (I) consisting of a portion of alpha interferon and a portion of omega interferon and glycosylated derivatives thereof. Wherein pvuII represents a restriction site of restriction enzyme pvuII common to α interferon and mutated ω interferon, A is an amino acid sequence encoded by the DNA sequence of α interferon located in the first half of the pvuII restriction site, and B is pvuII The amino acid sequence encoded by the DNA sequence of the ω interferon located in the latter part of the restriction site, or A is the amino acid sequence encoded by the DNA sequence of the ω interferon located in the latter part of the pvuII restriction site, and B is the amino acid sequence encoded by the pvuII restriction site. It is an amino acid sequence encoded by the DNA sequence of α interferon located in the second half. The hybrid interferon of claim 1, wherein the alpha interferon is IFN-α ₂ and the omega interferon is IFN-ω ₁ and glycosylated derivatives thereof. The hybrid interferon of claim 1, wherein the alpha interferon is IFN-α ₃ and the omega interferon is IFN-ω ₁ and the glycosylated derivatives thereof. The hybrid interferon and glycosylated derivatives of claim 2, wherein IFN-α ₂ is _r IFN-αA. The IFN-α _{2 /} ω ₁ hybrid interferon and its glycosylated derivatives according to claim 2, having the following amino acid sequence. The IFN-ω ₁ / α ₂ hybrid interferon and its glycosylated derivatives according to claim 2, having the following amino acid sequence. The IFN-α _{3 /} ω ₁ hybrid interferon and its glycosylated derivatives according to claim 3, having the following amino acid sequence. The IFN-ω ₁ / α ₃ hybrid interferon and its glycosylated derivatives according to claim 3, having the following amino acid sequence. The IFN-αA _/ ω ₁ hybrid interferon and its glycosylated derivatives according to claim 4, having the following amino acid sequence. The IFN-ω _{1 /} α A hybrid interferon and glycosylated derivatives thereof according to claim 4, having the following amino acid sequence. DNA molecules of sequences (I), (II), (III), (IV), (V) or (VI) encoding alpha and omega or hybrid interferon of omega and alpha and degenerate DNA molecules thereof. A vector containing the DNA molecule of claim 11 or a degenerate DNA molecule thereof. The vector according to claim 12, wherein the vector containing the DNA molecule is plasmid _P SYS 112, _P SYS 121, _P SYS 113 or _P SYS 131. A pharmaceutical composition comprising the hybrid interferon claimed in any one of claims 1 to 10 or a glycosylated derivative thereof. Use of the hybrid interferon claimed in any one of claims 1 to 10 or its glycosylated derivatives for the treatment of viral infections and malignant neoplastic diseases. The codon CAA, which encodes amino acid Gln of interferon omega, is also transformed into CAG, which also encodes Gln, to provide a recognition site of restriction enzyme pvuII in the gene sequence of interferonω without changing the base sequence of amino acids, and the mutated interferon Interferon alfa gene sequence, which contains the gene sequence of ω and the restriction enzyme pvuII recognition site, is cross-linked by pvuII crosslinking or by chemical DNA synthesis, the first half of interferonα and the second half of ω or the first half of interferonω and the second half of α A hybrid IFN structural gene is prepared, and the obtained hybrid gene is bound to an appropriate expression vector, the vector is transformed into an appropriate host, and the transformed host is cultured under the condition that the hybrid IFN structural gene can be expressed. Unlike the expressed hybrid interferon The method of Kim, characterized for producing a hybrid interferon or a glycosylated derivative as claimed in claim any one of Compounds 1 to 10. The method of claim 16, wherein the interferon omega is IFN-ω ₁ and the interferon alpha is IFN-α ₂ . The method of claim 16, wherein the interferon omega is IFN-ω ₁ and the interferon alpha is IFN-α ₃ . ※ Note: The disclosure is based on the initial application.